<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A critical analysis of the latest studies and meta-analyses dealing with antidementia agents, show that the efficacy of <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi>, galantamine, ginkgo biloba EGb 761, memantine, rivastigmine and <z:chebi fb="0" ids="45980">tacrine</z:chebi> in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> is adequately confirmed </plain></SENT>
<SENT sid="1" pm="."><plain>With the exception of <z:chebi fb="0" ids="45980">tacrine</z:chebi>, none of these substances are commonly associated with severe side effects </plain></SENT>
<SENT sid="2" pm="."><plain>In the case of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, the efficacy of ginkgo biloba EGb 761 and memantine has been demonstrated </plain></SENT>
<SENT sid="3" pm="."><plain>Studies on the effectiveness of the <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi> for this indication have been initiated </plain></SENT>
<SENT sid="4" pm="."><plain>Antidementia agents can delay progression of the disease by about 6 to 12 months </plain></SENT>
<SENT sid="5" pm="."><plain>Further studies are needed to confirm evidence of a prophylactic effect and a synergistic action of combinations </plain></SENT>
</text></document>